Surgery for Hypertrophic Obstructive Cardiomyopathy by Kokotsakis, Ioannis et al.
Surgery for Hypertrophic Obstructive 
Cardiomyopathy
Ioannis Kokotsakis, MD, Timotheos Sakellaridis, MD,  
Georgia Giannoulaki, MD
A B S T R A C T
Surgical treatment of hypertrophic obstructive cardiomyopathy (HOCM) comprises 
septal myectomy which though has been limited to patients with refractory symptoms 
and high resting gradients. Results of surgical intervention are well documented with 
dramatic reduction in left ventricular outflow tract gradient and resultant relief of 
symptoms in about 95% of patients. Transcoronary ablation of septal hypertrophy 
with alcohol is a newer percutaneous technique, designed to ablate hypertrophied car-
diac septal muscle through localized infarction, but its efficacy compared with that of 
surgical myectomy is uncertain. In the present article we briefly review the technique 
of septal myectomy and compare it with septal ablation, concluding that the standard 
septal myectomy still remains the preferred and proven therapy.
I N T R O D U C T I O N
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited disorder with 
variable expressivity, resulting in asymmetric septal hypertrophy and left ventricular 
outflow tract (LVOT) obstruction. Symptoms are similar to those of aortic stenosis 
and are due to left ventricular diastolic dysfunction and myocardial ischemia in the 
absence of epicardial coronary narrowing. Goals of treatment include symptomatic 
control, resolution of hemodynamic abnormalities and their sequelae, reduction of 
sudden cardiac death risk, and screening of family members. Left ventricular outflow 
tract obstruction at rest is a predictor of severe symptoms, heart failure, and death. 
The majority of patients are managed medically, predominantly with β-blockers and 
calcium channel blockers. Disopyramide, a negative inotrope, can be used in cases 
with persistently high resting gradients. To prevent sudden cardiac death, implantable 
cardioverter-defibrillators (ICDs) are used aggressively 1
Surgical treatment has been limited to patients with refractory symptoms and 
high resting gradients. Results of surgical intervention are well documented, with 
95% of patients being asymptomatic with accompanying dramatic reduction in the 
LVOT gradient. Transcoronary ablation of septal hypertrophy with alcohol – TASH 
procedure - is a newer percutaneous technique. It is designed to ablate hypertrophied 
cardiac septal muscle through localized infarction, but its efficacy compared with that of 
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surgical myectomy is uncertain. Surgery is not indicated in the 
absence of significant LVOT obstruction. Only those patients 
with symptoms refractory to medication and obstruction either 
at rest or with provocation are generally referred for surgery.2
S U R G I C A L  T E C H N I Q U E S
Several techniques for relief of obstruction in HOCM 
have been described ever since Cleland in 1958 started with 
transaortic myotomy, a procedure known better as Bigelow 
technique. Septal myectomy rather than simple myotomy was 
introduced by Morrow in 1961 and advanced over the years 
to the standard operation known as Morrow procedure. It was 
based on the assumption that the asymmetric septal hyper-
trophy was solely responsible for the left ventricular outflow 
tract obstruction. 3
Surgery for HOCM has evolved over the past four dec-
ades, from ventricular septal myotomy (i.e., without muscular 
resection), to the classic Morrow myectomy. More recently, 
an extended and more extensive myectomy (up to about 7 
cm long compared with 3 cm for the standard Morrow resec-
tion), combined with repair of mitral valve and submitral 
abnormalities, is practiced by some surgeons. Septal myectomy 
is performed through an aortotomy. A rectangular trough is 
created by first making two parallel longitudinal incisions in the 
basal septum near the nadir of the right coronary aortic cusp 
(RCC), septum beneath the commissure of the RCC and left 
coronary aortic cusp (LCC). Incisions are extended distally and 
then connected transversely proximally below the aortic valve 
and distally just beyond the level of mitral-septal contact and 
subaortic obstruction (with standard Morrow myectomy) or 
to mid-ventricular level at the base of papillary muscles (with 
extended myectomy), yielding 3 to 12 grams of septal muscle. 
It has been prudent practice to perform myectomy under in-
traoperative transesophageal echocardiographic guidance to 
directly monitor the efficacy of the resection (to identify the 
level of obstruction and distribution of septal hypertrophy) 
and allow for possible surgical revision.
Mitral valve repair, in addition to myectomy, may be most 
appropriate for selected patients with severe mitral regurgi-
tation caused by primary valvular disease (e.g., myxomatous 
or rheumatic or ruptured chordae). Occasionally, if intrinsic 
mitral valve disease is of sufficient severity to preclude repair, 
or the proximal septum is only mildly thickened and the risks 
for either septal perforation (by excessive muscular resec-
tion) or residual post-operative obstruction (by inadequate 
resection) are increased, then replacement with a low-profile 
mitral prosthesis without myectomy may be prudent. Mitral 
valve replacement is, however, not routinely recommended as 
a primary treatment for obstruction, because of the potential 
postoperative complications related to durability, throm-
boembolism, and anticoagulation.1 As an alternative to the 
transaortic approach, transatrial and transmitral myectomy 
has been attempted.4
Occasionally, greatly elongated and flexible mitral leaflets 
will contribute substantially to the generation of mitral septal 
contact. In such selected cases, mitral valve plication combined 
with myectomy has been performed to restrict mitral valve mo-
tion and allow for more complete relief of subaortic obstruc-
tion and mitral regurgitation. Septal myectomy also offers an 
opportunity to repair associated major cardiac lesions such as 
atherosclerotic obstructive coronary artery disease or forms of 
fixed aortic stenosis, or surgically treat atrial fibrillation with 
the MAZE procedure.
C L I N I C A L  R E S U L T S
Either alcohol ablation or myectomy offers substantial 
clinical improvement for patients with HOCM. Hemodynamic 
resolution of the obstruction and its sequelae is more complete 
with myectomy. Residual lesions after alcohol ablation might 
affect longer-term outcomes.
Septal myectomy is a safe, reliable, and durable method of 
eliminating LVOT obstruction in HOCM.5 It improves func-
tional status, reduces mitral regurgitation and normalizes life 
expectancy. It is the benchmark for ablative therapies and is 
our preferred method for treating this complex and fascinating 
disease. Earlier reports mentioned a mortality rate of 4%-
6%,6,7 more recent studies report mortality rates of less than 
2%5,8 The surgical results are much improved due to better 
anesthesia, myocardial protection during cardio-pulmonary 
bypass, and the use of intra-operative transesophageal echo-
cardiography. 9 The latter permits a thorough evaluation of 
the surgical result upon the interventricular septum and, if 
required, the mitral valve, before the patient leaves the op-
erating room. Complications of surgical myectomy include 
ventricular septal defect due to excessive removal of cardiac 
muscle, aortic regurgitation due to the transaortic approach 
and left bundle branch block or complete heart block requiring 
a permanent pacemaker.2,10,11
Alcohol ablation creates a strategically placed iatrogenic 
myocardial infarction (i.e., a scar). Currently published data 
suggest that procedural success is in the range of 75% to 80%, 
and among those successes, symptomatic improvement in the 
short-term and intermediate term is comparable with a my-
ectomy.12 However, despite the “less invasive” nature of this 
technique, the procedure-related morbidity and mortality are 
not lower than standard septal myectomy, and in some series 
they are higher. Importantly, there are no data indicating 
improved late survival after alcohol septal infarction. From a 
clinical investigation standpoint, it will be difficult for any pro-
cedure to show incremental benefit on the robust morbidity, 
mortality, hemodynamic, symptomatic, and survival benefits 
provided by standard septal myectomy.
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C O N C L U S I O N
Finally, among centers with substantial focus on HOCM in 
which both septal myectomy and septal ablation are performed, 
the standard septal myectomy is the preferred and proven 
therapy, whereas septal ablation is considered an alternative 
approach if surgical risk or other circumstances render surgery 
less attractive. A separate, but important consideration is risk 
of sudden death related to arrhythmia; although postopera-
tive rates of sudden death are very low, risk is not zero, and 
patients should be evaluated longitudinally regarding the need 
for medical treatment or ICD therapy, or both.12-19
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